OncoSelector

OncoSelector™-5FU

Available from Everist Genomics in March, 2012

The Role of Therapeutic Selection Tests in Personalized Medicine:

Therapeutic selection tests help physicians identify which therapeutics a patient’s disease is most likely to respond well to.  This is particularly important in cancer where the specific type of tumor a patient has and the presence or absence of specific proteins carried by an individual patient, will greatly influence which drug (or chemotherapeutic agent) will be the optimal treatment in terms of efficacy and safety.

OncoSelector-5FU:
OncoSelector-5FU is a new Everist Genomics molecular diagnostic test which will be available commencing in March 2012. OncoSelector-5FU will help physicians determine which colorectal cancer patients are likely to best respond to and tolerate the side-effects associated with the chemotherapeutic drug Fluorouracil (5FU)

To Find Out More:
If you are a physician and you would like to find out more about OncoSelector-5FU or to obtain free OncoSelector-5FU specimen collection kits please fill out the form at right.

  

I would like to know more about OncoSelector:

First name: Medical Specialty:
Last name: Email:
Street Address:
Telephone:
City:
State/Province:   ZIP/Postal Code:
I would like someone to contact me by phone or email to discuss the OncoSelector system
Please contact me to arrange a demonstration of OncoSelector at my office or hospital
Please have someone contact me to discuss securing a pre-release reservation for a OncoSelector system
Comments: